Safety and Efficacy of Axicabtagene Ciloleucel (axi‐cel) in Older Patients: Results From the Us Lymphoma Car‐t Consortium
Year: 2019
Type: article
Study design: Observational Study
Source: Hematological Oncology
DOI: 10.1002/hon.113_2630
Authors: D. Sano, L. Lekakis, L. Feng, L.J. Nastoupil, M.D. Jain, J.Y. Spiegel, S. Dahiya, Y. Lin, A. Ghobadi, M. Lunning, B.T. Hill, P. Reagan, O. Oluwole, J. McGuirk, A. Sehgal, A. Deol, A. Charalambos, A.H. Goy, J. Munoz, A. Cashen, N.N. Bennani, A.P. Rapoport, J.M. Vose, D.B. Miklos, F.L. Locke, S.S. Neelapu
Institutions: The University of Texas MD Anderson Cancer Center, University of Miami, Moffitt Cancer Center, Stanford Medicine, Stanford University, University of Maryland Medical Center, Mayo Clinic, Washington University in St. Louis, Washington University Medical Center, University of Nebraska Medical Center, Cleveland Clinic, University of Rochester Medicine, University of Rochester, Vanderbilt University Medical Center, The University of Kansas Health System, UPMC Hillman Cancer Center, University of Pittsburgh Medical Center, Wayne State University, The Barbara Ann Karmanos Cancer Institute, University of California, San Francisco, Hackensack University Medical Center, Banner MD Anderson Cancer Center
Language: English
Topic: CAR-T cell therapy research
Subfield: Oncology
Field: Medicine
Domain: Health Sciences
Open Access status: closed
OpenAlex ID: W2950909781